Some individuals even have acquired prior cytotoxic therapy, both as adjuvant cure or for metastatic disease. crofelemer increases levels of exemestane by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Crofelemer has the opportunity to inhibit CYP3A4 at concentrations envisioned within the intestine; unlikely to inhibit systemically because minimally absor... https://michelangeloj814ove5.tusblogos.com/profile